Clinical trials: Metabolic Management Center
Type 2 Diabetes Mellitus and Microalbuminuria
A Phase 2 Dose-finding Study of TAK-272 in Participants With Type 2 Diabetes Mellitus and Microalbuminuria
The purpose of this study is to test the efficacy and safety on daily oral doses of TAK-272 5 mg, 20 mg, 40 mg and 80 mg in patients with type 2 diabetes mellitus and microalbuminuria by randomized, double-blind…
- Trial name
- NCT02332824
- Testing
- TAK-272, Candesartan cilexetil
- Where
- 68 sites in Japan
- Volunteers
- 415 people
- Sponsor
- Takeda
Diabetes Mellitus, Hypertension
The Impact of Sharing Audio Recorded Clinic Visits on Self-management in Older Adults
The investigators will conduct a multi-site, two-arm, parallel-group, patient-randomized, blocked, controlled, pilot trial with a 3-month follow up in older adults (≥65 years) with diabetes and hypertension.
- Trial name
- NCT04344301
- Testing
- Audio recording
- Where
- 3 sites in United States
- Volunteers
- 91 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Metabolic Syndrome X
Effect of Ursolic Acid Administration on Insulin Sensitivity and Metabolic Syndrome
The metabolic syndrome is characterized by the presence of overweight/obesity, insulin resistance, hyperglycemia, dyslipidaemia and hypertension and an inflammatory state, which together increase the risk of developing…
- Trial name
- NCT02337933
- Testing
- Ursolic acid
- Where
- Mexico
- Volunteers
- 24 people
- Sponsor
- University of Guadalajara
Obesity
Integrating Online Weight Management With Primary Care Support
The goal of this project is to adapt an evidence-based online weight management program and integrate it with population management support from primary care practices.
- Trial name
- PROPS (NCT02656693)
- Testing
- Online weight management program, Population health management support
- Where
- United States
- Volunteers
- 840 people
- Sponsor
- Brigham and Women's Hospital
Hunter Syndrome
A Safety and Dose Ranging Study of Idursulfase (Intrathecal) Administration Via an Intrathecal Drug Delivery Device in Pediatric Patients With Hunter Syndrome Who Have Central Nervous System Involvement and Are Receiving Treatment With Elaprase®
Elaprase (idursulfase), a large molecular protein, is not expected to cross the blood brain barrier at therapeutic levels when administered intravenously.
- Trial name
- NCT00920647
- Testing
- Control, Idursulfase IT (1 mg), Idursulfase IT (10 mg)
- Where
- 3 sites in United States, United Kingdom
- Volunteers
- 16 people
- Sponsor
- Shire
Weight Gain, Obesity
The GEM (Goals for Eating and Moving) Study
The GEM intervention leverages the patient-centered medical home model by using the GEM tool to provide individually tailored, patient-centered care, promote standardized weight management counseling by health coaches and primary…
- Trial name
- GEM (NCT03006328)
- Testing
- GEM, Enhanced Usual Care
- Where
- United States
- Volunteers
- 489 people
- Sponsor
- NYU Langone Health
Dementia, Alzheimer Disease
Care Ecosystem: Navigating Patients and Families Through Stages of Care
This is a randomized clinical trial evaluating the benefits of a program that supports model care for persons with dementia and their family caregivers. Subjects were recruited from California, Nebraska and Iowa.
- Conditions
- Dementia, Alzheimer Disease, Dementia, Vascular, Lewy Body Disease
- Trial name
- NCT02213458
- Testing
- Navigated Care
- Where
- 2 sites in United States
- Volunteers
- 1,560 people
- Sponsor
- University of California, San Francisco
Cushing's Disease, Acromegaly
Study of Management of Pasireotide-induced Hyperglycemia in Adult Patients With Cushing's Disease or Acromegaly
The study was designed to investigate the optimal management of hyperglycemia developed during pasireotide treatment in participants with Cushing's disease or Acromegaly, which was not manageable with metformin.
- Trial name
- NCT02060383
- Testing
- Pasireotide s.c., Sitagliptin, Liraglutide
- Where
- 43 sites in United States, Belgium and 10 more
- Volunteers
- 249 people
- Sponsor
- Novartis Pharmaceuticals
Amyotrophic Lateral Sclerosis, Parkinson Disease
Physiological Flow of Liquids Used in Dysphagia Management (Neuro)
For individuals with neurodegenerative conditions, such as Amyotrophic Lateral Sclerosis and Parkinson disease, swallowing impairment (i.e., dysphagia) is a common and serious symptom.
- Conditions
- Amyotrophic Lateral Sclerosis, Parkinson Disease, Dysphagia
- Trial name
- NCT03192358
- Testing
- Videofluoroscopic Swallowing Examination, Tongue Strength Measurement
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University Health Network, Toronto